Other languages BioCryst Pharmaceuticals, Inc.

Equities

BCRX

US09058V1035

Market Closed - Nasdaq Other stock markets 04:00:00 2024-07-05 pm EDT			5-day change	1st Jan Change
6.52 ^USD	+1.72%		+5.50%	+8.85%

Jul. 03	Island Pharmaceuticals Acquiring Clinical-Stage Antiviral Molecule	MT
Jul. 01	BioCryst Pharmaceuticals, Inc.(NasdaqGS:BCRX) dropped from Russell Small Cap Comp Value Index	CI

Other languages

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Island Pharmaceuticals Acquiring Clinical-Stage Antiviral Molecule	Jul. 02
BioCryst Pharmaceuticals Says Drug Shows Evidence of Reducing Attacks Among Hereditary Angioedema Patients	Jun. 03
Sector Update: Health Care Stocks Advance Late Wednesday Afternoon	May. 15
BioCryst Pharmaceuticals Shares Rise 20% Following Disclosure of Executive Share Purchases	May. 15
BioCryst Says Orladeyo Granted Approval in Mexico	May. 13
BioCryst Pharmaceuticals, Inc. Announces Federal Commission for Protection Against Health Risks in Mexico Grants Approval for Oral, Once-Daily ORLADEYO	May. 13
BioCryst Presents New Real-world Evidence Showing Significant Reductions in Healthcare Resource Utilization Among Patients with HAE Following Initiation of ORLADEYO	May. 09
Sector Update: Health Care Stocks Higher in Late Afternoon Trading	May. 06
BioCryst Pharmaceuticals Shares Jump After Q1 Beat	May. 06
Biocryst Pharmaceuticals, Inc. Revises Revenue Guidance for the Year 2024	May. 06
BioCryst Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 06
BioCryst Pharmaceuticals, Inc. Announces Approval of ORLADEYO (berotralstat) by the Brazilian Health Regulatory Agency	Apr. 17
BioCryst Pharmaceuticals Q4 Adjusted Loss Narrows as Revenue Increases	Feb. 26
BioCryst Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 26
Biocryst Pharmaceuticals, Inc. Provides Earnings Guidance for the Full Year 2024	Feb. 26
BioCryst Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 26
BioCryst Launches Orladeyo (Berotralstat) in Italy	Feb. 19
BioCryst Pharmaceuticals Sees FY23, FY24 Orladeyo Sales Topping Prior Forecast; Eyes 2024 Operating Profit	Jan. 05
BioCryst Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2024	Jan. 05
BioCryst Pharmaceuticals, Inc. Announces Publication of Data from Open-Label Extension of the APeX-2 Pivotal Trial of ORLADEYO(R) (berotralstat)	Dec. 19

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages BioCryst Pharmaceuticals, Inc.

Equities

BCRX

US09058V1035

Other languages

Filters